# Tennessee lawmakers split as DOJ shift reignites push for medical marijuana rules > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/tennessee-medical-marijuana-legislation-updates-clinical-perspective/ > **Published:** 2026-05-19T18:33:09-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:06:02-04:00 > **Clinical Summary:** Clinical analysis of Tennessee medical marijuana legislation updates and what patients should know about cannabis treatment options in Tennessee. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. ⚒ Cannabis News  |  CED Clinic Medical Cannabis PolicyState RegulationClinical EvidencePhysician Practice Why This Matters Regulatory shifts at the federal level create clinical urgency for states like Tennessee that have not yet established [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) frameworks. Without clear state guidelines, clinicians lack standardized protocols for patient assessment, dosing, and safety monitoring — leaving physicians vulnerable and patients without evidence-based access. Clinical Summary Tennessee lawmakers are reconsidering [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) regulation following recent Department of Justice policy changes that signal reduced enforcement priorities. The state currently prohibits medical cannabis despite growing evidence supporting its use in specific conditions ([chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), epilepsy, PTSD). Legislative divisions reflect broader tensions between federal scheduling, state autonomy, and clinical evidence. Federal rescheduling or deschedule remains uncertain, but DOJ signaling typically precedes state-level legislative momentum. Dr. Caplan’s Take “*When federal policy moves, state legislatures follow — but medicine cannot wait for perfect legislation.* Clinicians in non-legal states should document patient interest, understand their state’s current liability landscape, and prepare for the inevitable regulatory evolution.” Clinical Perspective 🧠 For Tennessee clinicians: if medical cannabis regulation advances, the clinical priority will be establishing patient eligibility criteria, standardized product labeling, and pharmacist-led counseling protocols. Monitor pending legislation for language around qualifying conditions, THC:CBD ratios, and physician attestation requirements. Patient education now — about evidence, risks, and current legal status — will reduce pressure when legalization arrives. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Tennessee%20lawmakers%20split%20as%20DOJ%20shift%20reignites%20push%20for%20medical%20marijuana%20rule...%20%40drcaplan&url=https%3A//newschannel9.com/news/local/tennessee-lawmakers-split-as-doj-shift-reignites-push-for-medical-marijuana-rules)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//newschannel9.com/news/local/tennessee-lawmakers-split-as-doj-shift-reignites-push-for-medical-marijuana-rules)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Tennessee%20lawmakers%20split%20as%20DOJ%20shift%20reignites%20push%20for%20medical%20marijuana%20rule...%20--%20via%20%40drcaplan.bsky.social%20https%3A//newschannel9.com/news/local/tennessee-lawmakers-split-as-doj-shift-reignites-push-for-medical-marijuana-rules)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://newschannel9.com/news/local/tennessee-lawmakers-split-as-doj-shift-reignites-push-for-medical-marijuana-rules](https://newschannel9.com/news/local/tennessee-lawmakers-split-as-doj-shift-reignites-push-for-medical-marijuana-rules) Table of Contents - [FAQ](#FAQ)[What is CED Clinical Relevance #56?](#What_is_CED_Clinical_Relevance_56) - [What topics does this article cover?](#What_topics_does_this_article_cover) - [What does “Monitored Relevance” mean?](#What_does_Monitored_Relevance_mean) - [Who is the intended audience for this information?](#Who_is_the_intended_audience_for_this_information) - [Why is further evidence needed before clinical action?](#Why_is_further_evidence_needed_before_clinical_action) - [Related](#Related) ## FAQ #### What is CED Clinical Relevance #56? CED Clinical Relevance #56 is a monitored relevance designation indicating an early-stage or contextual signal regarding cannabis and clinical evidence. This classification means further evidence is needed before clinical action can be recommended. #### What topics does this article cover? The article covers medical cannabis policy, state regulation, clinical evidence, and physician practice. These interconnected topics address how cannabis is being evaluated and implemented in clinical settings. #### What does “Monitored Relevance” mean? Monitored Relevance indicates that the topic is being tracked and observed but lacks sufficient evidence for definitive clinical recommendations at this time. It represents an early signal requiring additional research and data collection. #### Who is the intended audience for this information? The article is intended for healthcare providers, clinical staff, and policy makers involved in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) through the CED Clinic. It provides guidance on current medical cannabis policies and emerging clinical evidence. #### Why is further evidence needed before clinical action? [Cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) is still evolving, and clinical applications require robust, peer-reviewed evidence to ensure patient safety and efficacy. The “Monitored Relevance” status reflects the need for more comprehensive studies before widespread clinical recommendations can be made. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).